Dingxin Wang1,2, Ron
Gaba3, Brian Jin4, Ahsun Riaz4, Robert
Lewandowski4, Robert Ryu4, Kent Sato4, Ann
Ragin4, Laura Kulik5, Mary Mulcahy6,7, Riad
Salem4,7, Andrew Larson4,7, Reed Omary4,7
1Siemens
Medical Solutions USA, Inc., Minneapolis, MN, USA; 2Center for
Magnetic Resonance Research , University of Minnesota, Minneapolis, MN, USA; 3Department
of Radiology, University of Illinois at Chicago, Chicago, IL, USA; 4Department
of Radiology, Northwestern University, Chicago, IL, USA; 5Department
of Hepatology, Northwestern University, Chicago, IL, USA; 6Department
of Medicine, Northwestern University, Chicago, IL, USA; 7Robert H.
Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
In this study, we tested the hypothesis that Transcatheter Intraarterial Perfusion (TRIP)-MRI monitored intra-procedural changes in tumor perfusion during transcatheter arterial chemoembolization (TACE) may predict future tumor response. Our results demonstrated that intermediate level of tumor perfusion reduction was associated with improved tumor response, and TRIP-MRI measured intro-procedural tumor perfusion reduction and Child-Pugh class were independent factors associated significantly with tumor response. TRIP-MRI, performed within an integrated MR-IR suite, may potentially serve as an objective predictor of future tumor response at the time of TACE procedure.